Sveriges mest populära poddar

Research To Practice | Oncology Videos

Hälsa och motion Medicin

Lung Cancer | Oncology Today with Dr Neil Love: Key Presentations in Lung Cancer from the 2022 ASCO Annual Meeting

28 min•24 augusti 2022

Featuring an interview with Dr Joshua Sabari, including the following topics:

Updates in the use of adjuvant targeted therapy for localized and metastatic non-small cell lung cancer (NSCLC); impact of the ADAURA trial (0:00)
Factors in the selection of second-line therapy for patients with and without driver mutations (10:30)
Role of immunotherapy for patients with driver mutations (14:26)
Recent updates in the use of antibody-drug conjugates for NSCLC (17:01)
Combining VEGF inhibition with other therapies for previously treated NSCLC (20:10)
Factors affecting response to immunotherapy in patients with lung cancer (23:19)

CME information and select publications

Fler avsnitt av Research To Practice | Oncology Videos

Oral SERDs for Breast Cancer | Erica Mayer, MD, MPH, FASCO

30 apr.•29 min

Oral SERDs for Breast Cancer | Aditya Bardia, MD, MPH

30 apr.•28 min

EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances

27 apr.•57 min

EGFR-Mutant Non-Small Cell Lung Cancer | Suresh S Ramalingam, MD

27 apr.•26 min

EGFR-Mutant Non-Small Cell Lung Cancer | Helena Yu, MD

27 apr.•30 min

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium

25 apr.•17 min

Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances

23 apr.•58 min

Prostate Cancer | Scott T Tagawa, MD, MS

23 apr.•25 min

Prostate Cancer | Andrew J Armstrong, MD, ScM

23 apr.•24 min

Menin Inhibitors in Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances

20 apr.•59 min

Research To Practice | Oncology Videos med Dr Neil Love finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.